Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2021-05-25 Capital/Financing Update
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
Manufacture of ATL1102 clinical supplies for Phase IIb trial 2 pages 100.3KB
Capital/Financing Update Classification · 90% confidence The document is an ASX announcement dated 26 May 2021 providing a progress update on the manufacture of clinical supplies for a Phase IIb clinical trial of ATL1102. It details manufacturing completion, formulation, and testing status, but does not contain financial data, regulatory certifications, or detailed financial results. It is a corporate update on manufacturing progress rather than a financial report, earnings release, or regulatory filing. The document is longer than 5,000 characters but is clearly an operational update. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is best classified as a Capital/Financing Update (CAP) because it relates to clinical supply manufacturing progress which is part of the company's capital project updates and operational financing activities in drug development. Confidence is high given the clear operational update nature and absence of financial statements or regulatory certifications.
2021-05-25 English
Proposed issue of Securities - ANP 5 pages 27.4KB
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding a proposed issue of securities by Antisense Therapeutics Limited. It details the number of securities to be issued, the type of issue (placement or other type), the issue date, and other related information such as approvals and fees. There is no financial performance data, management discussion, or detailed financial statements. The document is focused on informing about a capital raising or share issuance event. This fits the definition of a Capital/Financing Update (CAP). The document length and content confirm it is not a brief notice or a report publication announcement but a substantive announcement about a financing activity.
2021-05-06 English
Appendix 2A & Cleansing Notice 15 pages 410.4KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Appendix 2A Application for quotation of +securities' and references ASX Listing Rules and securities issuance. It is an application form for the quotation of securities on the Australian Securities Exchange (ASX). The content includes details about the entity, type of securities issued, and related regulatory compliance information. This type of document is a regulatory announcement related to capital markets activity, specifically the application for quotation of new securities. It is not a financial report, earnings release, or management discussion. It fits the category of Capital/Financing Update (CAP) as it relates to the issuance and quotation of securities, which is a capital market activity update.
2021-05-06 English
Quarterly Report and Appendix 4C 8 pages 339.0KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 28 April 2021, titled 'Quarterly Update & Appendix 4C'. It provides a quarterly update on company activities including regulatory meetings, clinical trial progress, director appointment, investor engagement, and broker research. Importantly, it includes the Appendix 4C, which is a quarterly cash flow report required under ASX Listing Rule 4.7B. The Appendix 4C contains detailed cash flow statements for the quarter ended 31 March 2021, including operating, investing, and financing activities, as well as reconciliation of cash and cash equivalents. The document is approximately 15,000 characters long and contains substantive financial data and analysis for the quarter, not merely an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR) as it is a comprehensive financial report for a period shorter than a full fiscal year with actual financial statements and analysis. Q3 2021
2021-04-27 English
US FDA Type C Meeting for ATL1102 in DMD 2 pages 85.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 23 April 2021 regarding a Type C meeting with the US FDA about the development of ATL1102 for Duchenne muscular dystrophy (DMD). It discusses the meeting outcomes, regulatory guidance, and future clinical study plans. The content is an update on regulatory and clinical development progress rather than a financial report, earnings release, or detailed investor presentation. It does not contain financial statements or detailed financial data. The document is a regulatory update announcement related to clinical development and regulatory interactions, fitting best under Regulatory Filings (RNS).
2021-04-22 English
Initial Director's Interest Notice - CG 2 pages 239.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the director's relevant interests in securities and contracts, specifically for a newly appointed director. The content focuses on disclosure of personal shareholdings and interests of a company director, which aligns with insider trading or director dealings. The document length is short and contains no financial statements or company performance data. Therefore, it fits the category of Director's Dealing (DIRS).
2021-03-23 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.